Paula Rodríguez

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 636 citations

Medicine, Hematology, Pharmacotherapy +15

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 385 citations · Full text

Medicine, Hematology, Pharmacotherapy +11

Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

Sheri Skerget, Daniel Peñaherrera, Ajai Chari et al. · Nature Genetics · 2024 · 75 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Sleep-Disordered Breathing Is Independently Associated With Increased Aggressiveness of Cutaneous Melanoma

Miguel Ángel Martínez‐García, Francisco Campos‐Rodríguez, Eduardo Nagore et al. · CHEST Journal · 2018 · 65 citations · Full text

Medicine, Dermatology, Oncology +13

Personalized Hemodynamic Resuscitation Targeting Capillary Refill Time in Early Septic Shock

Fernando Pálizas, Bernardo Lattanzio, Natalia Durandal et al. · JAMA · 2025 · 63 citations · Full text

Medicine, Perioperative Medicine, Hemodynamic Management +16